Loading
companiesCompany
OncoResponse
OncoResponse is a Seattle biotech that mines the antibodies of patients who responded exceptionally well to immunotherapy; OR502 blocks LILRB2 to re-educate the suppressive myeloid cells in tumours.
Also called: OncoResponse, Inc.
Overview
OncoResponse discovers antibodies from elite responders to cancer immunotherapy, working with MD Anderson Cancer Center. OR502 is a humanised antibody against LILRB2 (ILT4), an inhibitory receptor on macrophages and dendritic cells; blocking it shifts myeloid cells towards an anti-tumour state. OR502 is in a phase 1/2 trial alone and with cemiplimab in advanced solid tumours. Its earlier antibody OR2805 targets tumour-associated macrophages.
Headquarters
Seattle, Washington, US
Scorecard
All companies#482of 1244 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Monoclonal antibody
OR502 is a monoclonal antibody from OncoResponse, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.
drugs
Phase 2Monoclonal antibody